The initial success of the copyright undeniably revolutionized the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. Despite early returns were impressive, the end of patents and the emergence of discounted alternatives have weakened the customer base. Therefore, a thorough assessm